Fresenius Medical Care stock at EUR 39.78, down 2.52% premarket
Published on 11/12/2026 at 07:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat matters for investors
- Fresenius Medical Care combines dialysis treatment services with kidney-care products and related medical technologies.
- The company says its 5008X CAREsystem rollout in the United States had reached 227 clinics and more than 600,000 treatments by its latest investor update.
- Management confirmed its 2026 outlook in the investor update.
FMC stock slips before Xetra
Fresenius Medical Care stock traded at EUR 39.78 on Lang & Schwarz at 07:49 CET on Thursday, November 12, 2026, 2.52 percent below the Xetra close of Wednesday, November 11, 2026.
The company operates dialysis services and develops, manufactures and distributes products used in kidney care. Its portfolio includes dialysis machines, dialyzers, peritoneal dialysis systems, bloodlines, concentrates and related pharmaceuticals.
Fresenius Medical Care said in its investor relations update that the 5008X CAREsystem was available in 227 US clinics and had been used in more than 600,000 treatments. The company also confirmed its 2026 outlook and highlighted continued progress under its FME Reignite strategy.
Technology and reimbursement remain key
For investors, the rollout of new treatment technology and reimbursement trends remain important factors for earnings quality. Fresenius Medical Care has linked its recent operating performance to treatment economics, higher reimbursement rates and improvements in revenue-cycle management.
German equities trade against the backdrop of the DAX.
